Even before the pandemic struck and drug makers were seen as potential saviors, the pharmaceutical industry had slightly improved its battered image among patient groups, according to a new survey.

The survey found that 46% of patient advocacy groups thought that brand-name drug companies had developed an “excellent” or “good” reputation last year, up from 41% in 2018. This was also the best showing for pharma since the survey was started in 2011 by PatientView, a research firm that canvassed 1,850 patient groups from 95 countries between November 2019 and February 2020. They rated the reputations of 48 drug makers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I would not equate patient groups with the general public. Knowing what the general public thinks of drug companies might be a better indicator of which way their reputation is headed. Some patient groups have very cozy relationships with big drug companies. Still, anything positive from the survey is good.

    • Hi Daniel,

      Thanks for the note.
      And I agree that the reactions of patients groups should not be equated with the public at large for, presumably, obvious reasons. And yes, there are financial relationships, as noted in the post.

      It will be interesting to see the survey next year and still more interesting to watch for polls that gauge public perceptions more broadly of the industry.

      All best,
      ed at pharmalot

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy